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Summary
Paroxysmal nocturnal haemoglobinuria (PNH) is characterized by chronic,
uncontrolled complement activation resulting in elevated intravascular
haemolysis and morbidities, including fatigue, dyspnoea, abdominal pain,
pulmonary hypertension, thrombotic events (TEs) and chronic kidney
disease (CKD). The long-term safety and efficacy of eculizumab, a human-
ized monoclonal antibody that inhibits terminal complement activation,
was investigated in 195 patients over 66 months. Four patient deaths were
reported, all unrelated to treatment, resulting in a 3-year survival estimate
of 976%. All patients showed a reduction in lactate dehydrogenase levels,
which was sustained over the course of treatment (median reduction of
869% at 36 months), reflecting inhibition of chronic haemolysis. TEs
decreased by 818%, with 964% of patients remaining free of TEs. Patients
also showed a time-dependent improvement in renal function: 931% of
patients exhibited improvement or stabilization in CKD score at
36 months. Transfusion independence increased by 900% from baseline,
with the number of red blood cell units transfused decreasing by 547%.
Eculizumab was well tolerated, with no evidence of cumulative toxicity and
a decreasing occurrence of adverse events over time. Eculizumab has a
substantial impact on the symptoms and complications of PNH and results
a significant improvement in patient survival.
Keywords: eculizumab, paroxysmal nocturnal haemoglobinuria, phase III,
long-term therapy, haemolysis.
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare,
progressive and life-threatening haematopoietic stem cell
disorder. It is characterized by complement-mediated intra-
vascular haemolysis and a prothrombotic state (Brodsky,
2009; Hillmen et al, 2010). PNH may be diagnosed in
patients of all ages, but the median age is in patients in their
early 30s (Socie et al, 1996; Nishimura et al, 2004). Despite
best historical supportive care, including transfusions and
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anticoagulation management, PNH is fatal in approximately
35% of patients within 5 years of diagnosis (Hillmen et al,
1995; Socie et al, 1996; Kelly et al, 2011).
The disease arises from a somatic mutation in the phos-
phatidylinositol glycan class A gene (PIGA), which disrupts
synthesis of glycosylphosphatidylinositol (GPI), a molecule
that anchors proteins to cell membranes (Takeda et al,
1993). The mutation results in the reduction or complete
absence of the GPI-anchored complement regulatory proteins
CD55 and CD59, which renders the cells sensitive to comple-
ment-mediated destruction (Rother et al, 2005; Kelly et al,
2009). All blood cells are susceptible to complement-medi-
ated attack, although red blood cells are the most susceptible
to lysis (Parker, 1991; Pu & Brodsky, 2011).
Complement activation in PNH is manifested as chronic
haemolysis that leads to the release of free haemoglobin and
the subsequent depletion of nitric oxide. Consumption of
nitric oxide leads to vaso-occlusion and platelet activation
and results in the common morbidities seen in PNH, such as
fatigue, dyspnoea, recurrent abdominal pain, dysphagia, chest
pain and pulmonary hypertension. More importantly,
chronic haemolysis renders PNH patients at a greater risk of
thrombotic events (TEs), renal insufficiency and other organ
damage, and premature mortality. Compared with the
general population, patients with PNH have a 62-fold higher
risk of a TE (McKeage, 2011) and a six-fold greater risk of
chronic kidney disease (CKD) (Hillmen et al, 2010). TEs
have been reported to account for up to 67% of PNH-related
deaths (Hillmen et al, 2007), while CKD has been reported
to account for 8–18% of disease-related mortality (Clark
et al, 1981; Nishimura et al, 2004).
Historically, supportive care measures used in PNH, such
as transfusions, anticoagulation or long-term use of steroids
and pain medication, leave patients with a poor quality of
life and are associated with adverse events. In addition,
supportive care measures do not prevent the occurrence of
catastrophic events, such as thromboses and CKD, that have
recently been associated with elevated risk of premature mor-
tality (Hillmen et al, 2004, 2006, 2007, 2010; Rother et al,
2005; Brodsky et al, 2008; de Latour et al, 2009; Hill et al,
2010; Kelly et al, 2011).
Eculizumab, a humanized monoclonal antibody, inhibits
the terminal complement cascade by binding uniquely to
human complement protein C5, thereby inhibiting the for-
mation of pro-inflammatory, prothrombotic C5a, and C5b,
with subsequent inhibition of assembly of the membrane
attack complex (Hillmen et al, 2006; Brodsky et al, 2008).
Although eculizumab suppresses the terminal complement
system, the proximal complement system, responsible for
opsonization of microorganisms and clearance of immune
complexes, remains intact and fully functional (Rother et al,
2007). A series of multinational clinical trials demonstrated
that eculizumab therapy is well tolerated, leads to a rapid
and clinically significant reduction in intravascular haemoly-
sis and, thus, provides substantial clinical benefits (Hillmen
et al, 2004, 2006, 2007, 2010; Rother et al, 2005; Brodsky
et al, 2008; Hill et al, 2010). By inhibiting terminal comple-
ment activation and intravascular haemolysis, treatment with
eculizumab significantly reduces TEs (Hillmen et al, 2007),
transfusion requirements (Hillmen et al, 2006) and pulmo-
nary hypertension (Hill et al, 2010, 2012) and significantly
improves renal function (Hillmen et al, 2010), gastrointesti-
nal pain (Hill et al, 2005a) and patient quality of life
(Hillmen et al, 2006).
Clinical benefit occurs rapidly in patients with PNH
following the initiation of eculizumab. Here we report on con-
tinuous administration of eculizumab (for up to 66 months)
and the impact of long-term therapy on clinical outcomes in
PNH. In addition, we provide greater insight into the safety
profile of long-term eculizumab therapy for PNH.
Methods
Study design and patients
This manuscript reports on the long-term safety and efficacy
of eculizumab in 195 patients with haemolytic PNH who
had participated in one of three prospective parent trials:
the Phase II pilot study (Hillmen et al, 2004; Hill et al,
2005b) and its extensions, the Phase III TRIUMPH (Trans-
fusion Reduction Efficacy and Safety Clinical Investigation, a
Randomized, Multicenter, Double-Blind, Placebo-Controlled,
Using Eculizumab in Paroxysmal Nocturnal Haemoglobinu-
ria) study (NCT00122330) (Hillmen et al, 2006), or the
Phase III SHEPHERD (Safety in Hemolytic PNH Patients
Treated With Eculizumab: A Multi-Center Open-Label
Research Design) study (NCT00130000) (Hillmen et al,
2007; Brodsky et al, 2008). At the end of these initial stud-
ies, 187 of the 195 patients (959%) enrolled in an open-
label extension study (Fig 1). All patients had a minimum
of 10% PNH red blood cells at enrolment in the parent tri-
als and were vaccinated with a meningococcal vaccine at
least 14 d before the first eculizumab infusion in the parent
studies. It was recommended that all patients be revaccinat-
ed at intervals of between 25 and 3 years, with meningo-
coccal vaccine titre assays collected prior to and within
1–2 months of the revaccination. All three parent trials
employed the same dosing regimen: 600-mg infusions of
eculizumab every week for 4 weeks, followed 1 week later
by a single 900-mg dose, and then a maintenance dose of
900 mg every 14 (2) days until the end of the study. In
the extension study patients continued to receive the main-
tenance dose of eculizumab.
The first clinical investigation of eculizumab was an open-
label, 12-week, Phase II pilot study that enrolled 11 patients
at two UK study centres, all of whom continued into two
extension studies: the first of 52 weeks duration and the
second of 104 weeks duration. The positive outcomes from
this study (Hillmen et al, 2004, 2007) resulted in the initia-
tion of two pivotal phase III studies.
Long-Term Eculizumab Treatment in PNH
ª 2013 John Wiley & Sons Ltd 63
British Journal of Haematology, 2013, 162, 62–73
The first pivotal study, TRIUMPH, was a 26-week, double-
blind placebo-controlled trial that included 87 patients ran-
domized to either eculizumab (n = 43) or placebo (n = 44)
(Hillmen et al, 2006). Patients were required to have had at
least four transfusions during the previous 6 months for anae-
mia or anaemia-related symptoms, platelet counts
 100 9 109/l and lactate dehydrogenase (LDH) levels
 15-fold the upper limit of the normal range.
The open-label, single-arm SHEPHERD trial lasted
52 weeks and included 97 patients. The patient eligibility cri-
teria for this study were broadened to include patients with
fewer transfusion requirements (as low as one transfusion
within 24 months prior to initiating eculizumab treatment)
and more severe bone marrow dysfunction (platelet counts as
low as 30 9 109/l) (Hillmen et al, 2007; Brodsky et al, 2008).
The long-term extension study comprised a 104-week
treatment period and a 16-week post-treatment follow-up
period for any patients who terminated treatment early.
Patients who completed the 2-year long-term extension
before eculizumab was commercially available or accessible
were allowed to continue receiving the investigational
product until the drug was approved in their country.
Study endpoints
Efficacy assessments were performed at least every 2 weeks
from the time of initiation of eculizumab therapy in the
parent study. Efficacy measures included patient survival,
degree of haemolysis (as measured by blood LDH levels), TE
incidence rate, mean change from baseline in haemoglobin
and the number of units of transfused packed red blood cells
(PRBCs) administered. Assessments of renal function were
performed over the duration of the study by determining the
CKD stage using formulas for estimated glomerular filtration
rate (GFR) developed by the Modification of Diet in Renal
Disease Study Group (Levey et al, 1999; Stevens et al, 2006).
Specifically, stage 0 was defined as GFR >90 ml/min/173 m2
with no evidence of kidney damage; stage 1 as GFR >90 ml/
min/173 m2 with evidence of kidney damage; stage 2 as
GFR 60–90 ml/min/173 m2 with evidence of kidney damage
(proteinurea assessed by dipstick or abnormal imaging
findings); stage 3 as GFR 30–60 ml/min/173 m2; stage 4 as
GFR 15–30 ml/min/173 m2; and stage 5 as GFR <15
ml/min/173 m2. The number of transfusion-independent,
compared with transfusion-dependent, patients was assessed
over time. The baseline period was defined as the 6 months
prior to the initiation of eculizumab. At treatment evalua-
tion, transfusion-independent patients were defined as those
who did not require a blood transfusion during the previous
6 months, and transfusion-dependent patients had received
at least one blood transfusion in the previous 6 months.
Safety assessments included solicited monitoring of adverse
events (AEs), clinical laboratory tests and vital signs. AEs were
coded using the Medical Dictionary for Regulatory Activities
(MEDDRA) version 6.1, with AEs relating to infection and infec-
tion-related serious AEs (SAEs) tabulated separately consistent
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Fig 1. Phase II and III PNH clinical trials overview.
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with the expanded MedDRA preferred terms (http://www.
meddramsso.com). In addition, all AEs were reviewed for
events that could potentially be related to an infection and
classified accordingly. AEs were assessed for severity and classi-
fied as mild (events requiring minimal or no treatment and
not interfering with the patient’s daily activities), moderate
(events resulting in a low level of inconvenience or concern
with the therapeutic measures and possibly causing some
interference with functioning) or severe (events that are usu-
ally incapacitating and interrupting usual daily activities that
may require systemic drug therapy or other treatment).
An SAE was defined as any event that resulted in death,
was immediately life threatening, required inpatient hospital-
ization or prolongation of existing hospitalization, resulted
in persistent or significant disability/incapacity, or was a
congenital anomaly/birth defect. Important medical events
that did not result in death or require hospitalization and
were not life threatening may have been considered SAEs if,
based upon appropriate medical judgment, they required
medical or surgical intervention to prevent one of the
outcomes listed previously.
Statistical analyses
Baseline was defined as the pre-eculizumab value collected
from the parent study, except for those patients in the
TRIUMPH study who received placebo where baseline was
the value collected at the final visit of this study. Least-
squares mean changes from baseline in LDH levels were anal-
ysed using a repeated-measure analysis of variance model,
including time of treatment, parent study and parent study
treatment as fixed effects. The signed-rank test was used to
analyse mean changes from baseline in haemoglobin. Change
in CKD stage was analysed using the Mantel–Haenszel chi-
squared test. An improvement in renal function was defined
as a categorical documented reduction in CKD stage, and a
worsening in renal function was defined as a categorical
documented increase in CKD stage.
Comparisons of the reporting of AEs by patients during
the first 26 weeks of treatment with eculizumab and the last
26 weeks of treatment were tested using a one-tailed exact
McNemar test using matched-pairs data. For any patient
who remained in the study for <52 weeks, the incidence of
AEs reported during the first 26 weeks of treatment was
compared with the incidence of AEs from 26 weeks + 1 d
until the patient’s last dose of eculizumab.
Two patient populations were identified for statistical
analyses. All patients who had completed at least 26 weeks of
randomized treatment in one of the parent studies and had
received at least one dose of eculizumab in the extension
study were included in the safety population; patients from
this population who had no major protocol violations were
included in the per-protocol population. All analyses were
performed on an intent-to-treat basis. A P value of <0.05
was considered to be statistically significant.
Results
Study population and baseline characteristics
Baseline characteristics of all 195 patients at the start of the
parent trials are shown in Table I. Overall median age was
397 years (range: 18–85 years); more than 90% of the
patients were Caucasian and 54% were female. The majority
of patients (92%) were <65 years of age. Twenty-nine
percent of patients had a history of aplastic anaemia and
15% had a history of myelodysplastic syndrome.
The entire period of eculizumab administration across the
parent and extension trials was 66 months, although a
36-month cut-off was used for safety and efficacy assess-
ments to ensure that there were a sufficient number of
patients for robust statistical analysis. Of the patients
included in this 36-month cut-off, the overall median treat-
ment duration was 303 months, with a range of 100–
661 months (interquartile range: 262–331 months). During
maintenance dosing, 21 patients (108%) deviated from the
protocol dosing interval by receiving treatment <12 d apart
on at least one occasion. Of the original 195 patients, 19
patients (97%) discontinued treatment over a period of
66 months: nine discontinued because of an AE (see
‘Safety’), seven withdrew consent, two were discontinued
based on the decision of the investigator and one was
Table I. Baseline patient characteristics.
Parameter
Eculizumab
(n = 195)
Age, years
Median (range) 397 (183–850)
Mean (SD) 413 (1437)
Median disease duration
(range), months
815 (120–4838)
Gender, n (%)
Female 106 (544)
Male 89 (456)
Race, n (%)
Caucasian 176 (902)
Black 7 (36)
Asian 6 (31)
Other 6 (31)
History of aplastic anaemia, n (%) 56 (287)
History of myelodysplastic syndrome, n (%) 3 (15)
Haemoglobin, g/l
Mean (SE) 937 (114)
Range 480–1430
Lactate dehydrogenase, u/l
(upper limit of normal: 223 U/l)
Mean (SE) 22933 (8438)
Median 2129
Range 499–10 300
SD, standard deviation; SE, standard error.
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noncompliant with the protocol (Fig 1). Eight of the discon-
tinuations (six withdrawn consents and two AEs) occurred
during a parent trial, and the remaining 11 discontinuations
(seven AEs, two investigator’s decision, one withdrawn con-
sent, one non-compliance) occurred during the long-term
extension study.
Intravascular haemolysis
All patients showed a rapid decrease from baseline in serum
LDH, a marker for intravascular haemolysis, which was
generally sustained with continued treatment, although
throughout the course of the study some patients did have
transient increases in LDH. Prior to the first administration
of eculizumab, median LDH concentration was 2129 u/l
(range: 499–10 300 u/l; upper limit of normal: 223 u/l). One
month after eculizumab treatment initiation, median LDH
decreased to 263 u/l (range: 93–1208 u/l; P < 00001; Fig 2),
a relative reduction of 876%. This decrease was maintained
with sustained eculizumab treatment; the median LDH value
at 36 months was 279 u/l (range: 88–1417 u/l), a relative
reduction from baseline of 869%.
Plasma levels of eculizumab and haemolytic activity were
reviewed for 140 patients: 43 patients from the TRIUMPH
study and 97 patients from the SHEPHERD trial. Following
the first dose of eculizumab, trough concentrations <35 lg/
ml were observed in 49 of 135 patients (363%) with available
samples. Overall, 36 of these 49 patients (735%) exhibited
haemolysis as measured by a validated pharmacodynamic
assay (haemolysis >20%). Multiple occurrences of trough ecu-
lizumab concentrations <35 lg/ml were observed in 14 of 140
reviewed patients (100%). These patients generally had more
rapid eculizumab clearance (>04 ml/h/kg) or shorter ecu-
lizumab half-life (<130 h) than the respective median values
of the trial populations as a whole.
None of the patients with breakthrough haemolysis dis-
continued treatment with eculizumab. In seven of the 14
patients (500%), the breakthrough haemolysis was success-
fully mitigated, as evidenced by reductions in LDH concen-
trations, by decreasing the eculizumab dosing interval to
<14 d. None of these patients experienced SAEs relating to
haemolysis. In the whole population, 21 of 195 patients
(108%) had a median of 22 decreases (range: 3–124) in
dosing intervals.
Haemoglobin levels and transfusion requirements
Treatment with eculizumab resulted in a steady increase in the
serum haemoglobin concentration from baseline (937 g/l),
including a mean increase from baseline of 55 g/l (range:
320 to 550 g/l) to 992 g/l after 2 weeks of treatment and
10∙4 g/l (range: 420 to 810 g/l) to 1047 g/l by 24 months,
which was maintained at 36 months (Table II). The percent-
age of patients who achieved transfusion independence
increased with sustained treatment (Fig 3). The percentage of
patients achieving transfusion independence was 82∙1% (64 of
78) by the last 6 months of treatment, compared with only
8∙2% (16 of 195) in the 6 months prior to the start of treat-
ment, a relative increase of 90.0%. Fourteen of 78 patients
(17∙9%) continued to require transfusions between months 30
and 36. Despite the need for transfusions, these 14 patients
maintained a significant reduction in LDH from baseline levels
(P < 00001), and the number of units of PRBCs transfused
over the course of the study significantly decreased from a
mean of 11∙2 units in the 6 months prior to starting ecu-
lizumab to 3∙5 units between months 30 and 36 (P = 00001).
The change from baseline in the number of units of PRBCs
administered to all patients receiving transfusions over the
course of the study is presented in Table II.
Thrombotic events
Prior to initiation of eculizumab, 63 of 195 patients (323%)
experienced 124 TEs, both venous and arterial, over a total
of 1683 patient-years. These TEs included deep-vein throm-
bosis, hepatic vein (Budd-Chiari syndrome), cerebrovascular
accident, mesenteric thrombosis and pulmonary embolism.
The percentage of patients free from TEs increased from
677% before treatment to 964% during treatment: seven
patients (36%) reported a total of 10 TEs over 4671
patient-years. Of these seven patients, five had a history of
TEs prior to starting treatment with eculizumab and four
were receiving concomitant anticoagulation therapy (includ-
ing warfarin and low-molecular-weight heparins). Of the 10
TEs reported during eculizumab treatment, five were
reported as thrombophlebitis/deep vein thrombosis (three
events occurred in the same patient), one as deep vein
thrombosis, one as retinal vein thrombosis and one as a
possible thrombosis in a fistula. The remaining patient expe-
rienced portal vein thrombosis and splenic infarcts. The
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Fig 2. Lactate dehydrogenase level, a marker of intravascular haem-
olysis, was rapidly and consistently reduced from baseline (P < 0001
at all time points from 1 month) following initiation of eculizumab
therapy. Dashed line represents the upper limit of the normal range
(103–223 u/l). The decrease in number of patients was due to the
transition of patients to commercially available eculizumab. LDH,
lactate dehydrogenase.
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median time from the first dose of eculizumab to the first
TE was 646 d (approximately 21 months), with a range of
170–876 d (approximately 56–290 months).
A time-matched analysis showed that in the 4671 patient-
years prior to eculizumab treatment, there were a total of
52 TEs reported in 25 patients. The administration of
eculizumab reduced the TE incidence rate from 1113 events
per 100 patient-years to 214 events per 100 patient-years, a
relative reduction of 818% (P < 00005).
Overall, 98 patients (503%) were treated with anticoagu-
lants prior to or coincident with eculizumab: 11 patients
before the start of the study, 84 patients both before and
during treatment with eculizumab and three patients during
the study following a TE. Of the 95 patients who were trea-
ted with an anticoagulant prior to the start of the study, 58
(611%) experienced at least one TE before receiving
eculizumab. Eleven patients, six of whom had a prior history
of TEs, discontinued anticoagulant therapy while receiving
eculizumab. None of these 11 patients experienced a TE after
discontinuation of anticoagulant therapy.
Table II. Mean number of packed red blood cells transfused and haemoglobin concentrations throughout the study.
Study period,
months
Units of packed red blood cell transfused Haemoglobin (g/l)*
n
Mean (SE)
[range]
Mean (SE)
[range] change
from baseline P value n
Mean (SE)
[range]
Mean (SE)
change from
baseline P value
Baseline 164 53 (022)
[1–13]
195 937 (114)
[48–143]
0–3† 74 44 (033)
[1–13]
15 (038)
[8 to 6]
00001 195 992 (105)
[64–136]
55 (096)†
[32 to 55]
<00001
3–6 76 47 (037)
[1–19]
15 (042)
[9 to 9]
00007 193 1016 (115)
[65–146]
77 (141)
[34 to 56]
<00001
6–9 61 48 (040)
[2–14]
11 (050)
[11 to 9]
00293
9–12 58 46 (041)
[2–18]
17 (054)
[1–13]
00025 190 1005 (123)
[36–152]
68 (151)
[54 to 55]
<00001
12–15 62 36 (029)
[1–12]
25 (049)
[9 to 10]
00001
15–18 50 42 (032)
[1–11]
20 (055)
[11 to 6]
00006 189 1030 (121)
[63–168]
88 (145)
[36 to 80]
<00001
18–21 50 43 (051)
[1–19]
21 (065)
[11 to 15]
00022
21–24 42 46 (061)
[1–17]
14 (064)
[11 to 11]
00333 178 1047 (123)
[65–169]
104 (159)
[42 to 81]
<00001
24–27 37 40 (049)
[1–13]
29 (065)
[11 to 4]
<00001
27–30 30 44 (095)
[1–24]
15 (098)
[9 to 18]
01298 135 1067 (144)
[66–159]
111 (186)
[30 to 71]
<00001
30–33 10 31 (055)
[1–7]
30 (065)
[6 to 1]
00013
33–36 7 24 (030)
[2–4]
36 (113)
[10 to 1]
00196 86 1056 (179)
[64–146]
95 (220)
[31 to 68]
<00001
SE, standard error.
*Haemoglobin assessment at the end of corresponding study period.
†Haemoglobin assessment occurred 2 weeks after treatment initiation.
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Fig 3. Percentage of transfusion-independent and transfusion-depen-
dent patients over time. Transfusion-independent patients were those
who did not require a blood transfusion during the previous
6 months; transfusion-dependent patients had received at least one
blood transfusion in the previous 6 months.
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Chronic kidney disease
Chronic kidney disease stages (National Kidney Foundation,
2002) were assessed following each 6-month eculizumab
treatment period. Previous reports on this patient population
have demonstrated that prior to eculizumab treatment, 64%
of patients had evidence of CKD (Hillmen et al, 2010). There
was a time-dependent improvement in renal function. The
percentage of patients showing improvement, worsening or
no change in CKD was 254%, 61% and 685% respectively,
at 6 months compared with 448%, 69% and 483% respec-
tively, at 36 months. Overall, following 36 months of treat-
ment with eculizumab, 931% of patients showed either an
improvement or stabilization in CKD, and patients were
significantly more likely to experience an improvement than
a worsening in renal function (P = 0015).
Patient survival
Four of the 195 patients died while on eculizumab treatment;
the Kaplan–Meier estimate of patient survival at 36 months
was 976% [95% confidence interval (CI), 937–991%],
which was sustained out to 66 months (Fig 4). Mean dura-
tion of therapy with eculizumab was 399 d (range:
60–720 d). Three deaths were caused by concomitant condi-
tions: chronic myelomonocytic leukaemia in a 71-year-old
patient who had a history of myelodysplasia and died after
208 d of eculizumab therapy; metastases of pre-existing
stomach adenocarcinoma in a 63-year-old patient who died
after 609 d of therapy; and cerebral herniation in a 31-year-
old patient who died after 60 d of therapy. During in-patient
care for a pulmonary embolism, following a series of hospi-
talizations for a disc prolapse, pneumonia and renal failure,
the patient started hyperventilating with his pupils becoming
dilated. A computerized tomography scan of the brain
revealed a marked left hemorrhagic cerebral arterial media
infarct with clear signs of cerebral herniation and the start of
cerebrospinal fluid block. The last assessment of LDH levels,
almost 4 weeks prior to the event, were below the patient’s
chronic baseline haemolytic state, leading the investigator to
conclude that no serious haemolysis was present at that time.
The fourth patient, a 35-year-old with unconfirmed aplas-
tic anaemia who had received therapy for 720 d, experienced
an arteriovenous thrombosis of the small bowel. The investi-
gator decided to discontinue treatment with eculizumab
because of the patient’s aplastic anaemia; the patient experi-
enced the TE 19 d after the last eculizumab dose, and died
with clinical symptoms of sepsis following resection of the
small intestine. Further details relating to this patient have
been previously reported (van Bijnen et al, 2012). None of the
deaths were considered related to treatment with eculizumab.
Safety
Results from this study indicated that eculizumab was well
tolerated by patients with PNH. Table III lists AEs that were
reported in at least 10% of patients, regardless of relationship
to treatment. The most frequently reported AEs were head-
ache, nasopharyngitis and upper respiratory tract infection,
each reported in more than 40% of patients. The majority of
AEs (913%) were mild to moderate in severity.
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Fig 4. Long-term survival with eculizumab therapy.
Table III. Treatment-emergent adverse events reported in  10% of
patients.
Adverse event
Number (%)
of patients
(n = 195)
Patients reporting at least one adverse event 194 (995)
Headache 107 (549)
Nasopharyngitis 97 (497)
Upper respiratory tract infection 80 (410)
Diarrhoea 68 (349)
Nausea 63 (323)
Vomiting 50 (256)
Back pain 48 (246)
Abdominal pain 43 (221)
Arthralgia 43 (221)
Oropharyngeal pain 42 (215)
Pyrexia 40 (205)
Cough 39 (200)
Dizziness 39 (200)
Pain in extremity 39 (200)
Influenza-like illness 34 (174)
Urinary tract infection 33 (169)
Viral infection 30 (154)
Constipation 29 (149)
Contusion 29 (149)
Myalgia 29 (149)
Fatigue 25 (128)
Abdominal pain upper 24 (123)
Insomnia 23 (118)
Sinusitis 23 (118)
Episataxis 21 (108)
Oedema peripheral 20 (103)
Pruritus 20 (103)
Rash 20 (103)
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Serious AEs were reported in 75 of the 195 patients
(385%), with some of the most frequently reported serious
AEs, such as haemolysis, abdominal pain and anaemia, typi-
cally seen in patients with PNH. These events generally
occurred at times of biological stress, most typically in con-
junction with an infection. Other serious AEs reported by at
least 2% of patients were pyrexia (46%) and viral infection
(31%). Cholecystectomies were reported in six of the 195
patients (31%), and one patient developed chronic myelo-
monocytic leukaemia, resulting in the death of the patient.
Of the 19 patients who discontinued treatment, five
(263%) discontinued as a result of a nonfatal AE. Two
patients became pregnant, one patient developed myelodys-
plastic syndrome, one patient had meningococcal sepsis (see
Table IV) and one patient had, in the opinion of the investi-
gator, a worsening of PNH. This patient suffered from diabe-
tes and had persistent anaemia and impaired renal function,
but without reticulocytosis. Of note, three of these 19
patients (158%) experienced a TE within 8 weeks of their
last dose of eculizumab, with clinical details for one of these
patients having been previously described (van Bijnen et al,
2012). In the two patients who became pregnant, eculizumab
was received for the first 4 and 5 weeks of gestation. Both
pregnancies were without complication and resulted in the
delivery of healthy babies without any adverse effects from
eculizumab treatment (Kelly et al, 2010).
Three of the patients included in this study had a history
of myelodysplastic syndrome (MDS) prior to treatment with
eculizumab. At the time of last follow-up, one patient had
spontaneous resolution of the disorder 6 years after onset, one
patient was alive and had transitioned to commercially avail-
able eculizumab and, as mentioned previously, one patient
developed chronic myelomonocytic leukaemia and subse-
quently died. A fourth patient was diagnosed with MDS during
treatment with eculizumab and was withdrawn from the study
prior to receiving a bone marrow transplantation; this patient
did not show any signs of serious haemolysis in the 12 weeks
of follow-up following discontinuation of eculizumab.
Forty patients (205%) reported a total of 67 serious infec-
tion-related treatment-emergent AEs, none of which were
fatal. Table IV presents all serious infection-related events
reported in two or more patients. The most frequently
reported events were pyrexia (reported in nine patients) and
viral infection (reported in six patients). There was one case
of staphylococcal infection, which was successfully treated
with cefazolin sodium and two doses of vancomycin,
although the patient subsequently withdrew from the study.
Two cases of meningococcal sepsis were reported during
treatment, an infection rate of 0∙42 per 100 patient-years.
One was a serotype B infection that occurred in a 24-year-
old male patient 353 d after the initiation of eculizumab.
This patient had received a quradivalent vaccine against ser-
otypes A, C, W135 and Y. The infection was successfully
treated with several antibiotics, including imipenem, vanco-
mycin, ceftriaxone and penicillin; the range of antibiotics
used was because of bacterial sensitivity and the resistance
pattern in the local hospital flora. This patient remained in
the study and continued to receive eculizumab. The other
case occurred in a 54-year-old female patient 416 d after
eculizumab treatment was initiated and was due to serotype
Y or W135 (further serotyping was not possible in this
patient’s country). This patient had been vaccinated against
serotypes A and C. This infection was successfully treated
with meropenem, vancomycin, ceftriaxone and ciprofloxa-
cin, although the patient discontinued treatment on the
advice of the investigator. Of note, neither of the patients
with meningococcal sepsis had received vaccination against
the specific strain of their infection, at the time of the
infections serum bactericidal antibody values were within an
appropriate range and both infections resolved with treat-
ment and without sequelae. In neither case was the
meningococceal infection due to failure of the vaccine.
All AEs coded as pyrexia were considered related to infec-
tion even if an identifiable infection was not diagnosed at the
time of the fever. Overall, there were 38 events of pyrexia
reported in 22 patients, the majority of which (26 of 38;
684%) were mild in severity, whereas only three of 38 events
(79%) were considered severe. As previously mentioned,
nine patients (46%) had pyrexia events reported as SAEs,
which included all the events considered to be severe. All
events of pyrexia resolved without sequelae.
Adverse events related to treatment infusion were reported
in 71 patients (364%). Peripheral oedema, pruritus and rash
were the most frequently reported AEs of this type, each
occurring in a total of 20 patients (103%). None of the AEs
associated with treatment infusion resulted in the discontinu-
ation of eculizumab.
In order to investigate if long-term treatment with ecu-
lizumab increased the incidence of any individual or cate-
gory of AE or whether eculizumab was associated with
Table IV. Serious infection-related treatment-emergent adverse
events reported during eculizumab therapy (n = 195).
Adverse event
Number (%)
of patients
Mean onset
(days)*
Pyrexia 9 (46) 446
Viral infection 6 (31) 477
Lower respiratory tract infection 3 (15) 833
Urinary tract infection 3 (15) 878
Cellulitis 2 (10) 235
Meningococcal sepsis 2 (10)† 385
Pneumonia 2 (10) 456
Respiratory tract infection 2 (10) 664
Sepsis 2 (10) 604
Septic shock 2 (10) 312
Viral gastroenteritis 2 (10) 419
*Mean interval between date of first eculizumab dose until the
adverse event onset date.
†One patient discontinued treatment.
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cumulative toxicity, the incidence of AEs (irrespective of
relation to treatment) reported during the first 26 weeks of
eculizumab treatment was compared with the last 26 weeks
of treatment (Table V). Overall, significantly fewer patients
reported at least one AE in the last 26 weeks of treatment
(n = 145) than in the first 26 weeks of treatment (n = 189;
P < 0001), and no individual AE was reported by a statisti-
cally significantly greater number of patients during the last
26 weeks than during the first 26 weeks of treatment with
eculizumab. Although this analysis included patients who
had a total treatment duration of <52 weeks, the mean
(median) observation times of 2600 (260) and 2586 (260)
weeks for the first and last observation periods respectively,
indicated that the reduction in number of AEs seen in the
last 26 weeks of therapy was not due to the reporting of AEs
over a shorter observation time.
Assessments of clinical laboratory tests and vital signs did
not reveal any consistent or clinically significant mean
changes or any obvious treatment effect on these parameters.
There were small increases in direct bilirubin concentrations,
although median levels of total bilirubin remained essentially
unchanged.
Discussion
The results from this study demonstrate the long-term safety
and efficacy of chronic eculizumab treatment in a large
cohort of patients with PNH (n = 195). The median
eculizumab treatment duration was 303 months, with a
maximum duration of 66 months. Inhibition of terminal
complement activity with eculizumab has previously been
reported to rapidly and significantly reduce chronic haemoly-
sis, leading to reductions in transfusion requirements
(Hillmen et al, 2006) and TEs (Hillmen et al, 2007), as well
as improvements in renal function (Hillmen et al, 2010). The
current study shows that these results are sustained with
long-term treatment.
Thrombotic events are a severe and life-threatening com-
plication of PNH and are reportedly the most frequent cause
of death in patients with PNH (Hillmen et al, 2007). TE has
been shown to be a significant risk factor for early mortality
(relative risk: 154; 95% CI, 93–254; P < 0001) in
untreated patients (de Latour et al, 2008). Furthermore, fol-
lowing the occurrence of a first TE, there is a greater risk of
subsequent TEs, which places patients with a history of TE
at a heightened risk of premature mortality (Nishimura et al,
2004; de Latour et al, 2008). Given that TE in PNH patients
appears to be related to severe and ongoing uncontrolled ter-
minal complement activation, management of TE is difficult
in PNH patients, as many continue to report TE despite
prophylactic use of anticoagulation therapies (Moyo et al,
2004; de Latour et al, 2008; Kelly et al, 2011). We observed
an 818% reduction in the incidence of TEs with long-term
eculizumab treatment. Eighty-four patients in this study
received concomitant anticoagulant therapy, which was dis-
continued in 11 patients. Despite six of these 11 patients
having a history of TE, none of them experienced a TE fol-
lowing withdrawal of anticoagulation therapy while receiving
eculizumab alone. This experience is consistent with other
reports (Emadi & Brodsky, 2009; Kelly et al, 2011).
Thrombotic events were observed in 16% (3 of 19) of
patients who discontinued treatment with eculizumab, all
within 8 weeks of taking their last dose. This finding high-
lights the importance of adherence to eculizumab treatment
at the recommended dose and schedule over the long term,
as continuous therapy is paramount in maintaining sustained
inhibition of the underlying uncontrolled terminal comple-
ment activation. If discontinuation of eculizumab therapy
becomes necessary, the potential risk of thrombosis as well as
possible preventive measures should be considered.
Chronic kidney disease in PNH patients is caused by sev-
eral factors, including chronic exposure to free haemoglobin,
which increases renal accumulation of haemosiderin, tubulo-
interstitial inflammation and kidney damage (Nath et al,
2001). Renal impairment is known to progress over time
(Hillmen et al, 2010) and is associated with an increase in
mortality (Kim et al, 2011). Continued improvement in
CKD was observed with sustained eculizumab treatment,
Table V. Adverse events reported at a significantly different inci-
dence in the first and last 26 weeks of treatment with eculizumab*.
Adverse event
Number of patients
P value†
First 26
weeks
Last 26
weeks
Any event 189 145 <0001
Headache 87 20 <0001
Nasopharyngitis 47 32 0029
Nausea 33 21 0029
Constipation 14 3 0006
Back pain 20 9 0031
Arthralgia 17 8 0032
Muscle spasms 9 0 0002
Dizziness 17 8 0039
Pyrexia 18 9 0032
Epistaxis 12 4 0011
Fatigue 12 4 0029
Insomnia 10 2 0019
Respiratory tract infection 7 0 0008
Oral herpes 8 1 0020
Chest pain 6 1 0031
Haematoma 6 1 0031
Lethargy 5 0 0031
Toothache 5 0 0031
*For patients who received eculizumab for a total of <52 weeks, the
incidence of adverse events in the first 26 weeks was compared with
the period from the start of the 27th week until the last dose of
treatment. Only events for which there was a statistically significant
difference between the treatment periods are reported.
†P values determined from one-tailed exact McNemar test for
matched-pairs data.
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with 448% of patients showing improvement after
36 months of treatment, compared with 244% showing
improvement in CKD after only 6 months of treatment. The
improvement in renal function in all nine patients with
early-stage CKD (stage 1–2) over 36 months suggests that
patients treated with eculizumab at earlier stages of kidney
damage have a greater likelihood of improvement in renal
function, and there is evidence that sustained long-term
therapy with eculizumab can reverse early stage renal damage
sustained prior to treatment initiation. These are unique
findings in a patient population known to be at risk for pro-
gressive decline in renal function (Hillmen et al, 2010), and
they suggest that eculizumab may have a protective role that
can lead to improvement in, or less progression of, renal
disease.
Reduction in the incidence of TE and CKD, the two
major causes of death in PNH, by administration of ecu-
lizumab would be expected to lead to improved patient
survival. In the current prospective, multinational study in a
large cohort of 195 patients, we demonstrated a patient sur-
vival of 976% (95% CI, 937%–991%) at 3 years, which
was maintained over 66 months of eculizumab treatment.
This result is similar to the 5-year survival rate of 955%
observed in a single-centre, retrospective analysis of 79
patients (Kelly et al, 2011). These survival rates seen with
eculizumab therapy are a substantial improvement over his-
torical 5-year survival rates of approximately 65% in PNH
patients with evidence of haemolysis (Hillmen et al, 1995;
Kelly et al, 2011) and are similar to survival rates of age-
and sex-matched healthy subjects (Kelly et al, 2011). These
results further emphasize the role of uncontrolled comple-
ment activation in the pathophysiology of PNH-related
mortality.
Long-term treatment with eculizumab also resulted in sus-
tained haematological improvement in patients. Transfusion
independence was achieved by 52% (102 of 195) of patients
within the first 6 months of treatment, which increased to
82% by the last 6 months of treatment. The number of units
of PRBCs transfused was reduced by 55% over the 36-month
period. In addition, there was a continuous improvement in
haemoglobin levels, which was achieved despite the reduction
in transfusions.
The standard eculizumab maintenance dose of 900 mg
every 14  2 d was sufficient to maintain inhibition of
haemolysis in 89% of patients. In the 21 patients who did
report breakthrough haemolysis, shortening the dosing
interval to <14 d was sufficient to maintain inhibition of
haemolysis, and none of these patients discontinued treat-
ment because of a lack of therapeutic effect. It is important
that patients be monitored for any signs or symptoms of
breakthrough haemolysis so that the dosing can be adjusted
accordingly or, in cases of persistent breakthroughs, to
ensure the patient has not developed human anti-human
antibodies (HAHA) or neutralizing antibodies to ecu-
lizumab. Subsequent to the end of the study, a more
sensitive analysis became available for the identification of
HAHA in patients receiving eculizumab. With this new
analysis, two of the patients in the long-term extension
study were found to have low positive values for neutraliz-
ing antibodies, which exceeded the prespecified threshold
for the in vitro assay (data not shown). This finding had no
impact on the clinical response to eculizumab therapy or
on the pharmacokinetic and pharmacodynamic effects of
eculizumab, which continued to block complement activity.
Eculizumab was well tolerated over the long term and
demonstrated a positive safety profile. Although nearly all
patients reported at least one AE, this is to be expected con-
sidering the duration of the study; importantly, discontinua-
tion from treatment due to a nonfatal AE was seen in only
five patients (26%) over the entire period of study. With no
comparator group in this open-label extension, we compared
the AE rate of the early treatment group with that of the
later treatment group to understand the risk of long-term
eculizumab treatment. The probability of a patient experienc-
ing one or more AEs was significantly lower in the last
6 months of the eculizumab treatment period than in the
first 6 months of therapy. This suggests that there is no
cumulative toxicity with long-term administration of ecu-
lizumab and that the risk–benefit profile of eculizumab
improves with extended use. Serious infection-related AEs
were observed throughout the study, although there was no
evidence that their occurrence was related to time on
eculizumab treatment.
There is an increased incidence of infections with
N. meningitidis in individuals with genetic deficiencies of
C5–C9 (Figueroa & Densen, 1991). Thus, blocking terminal
complement activity with eculizumab increases a patient’s
susceptibility to meningococcal infections. Two cases of
meningococcal sepsis were reported during the approxi-
mately 467 patient-years of exposure to eculizumab. Both
patients were successfully treated without sequelae. Patient
education on the signs and symptoms of potential menin-
gococcal infections remains important to ensure that any
infections are identified as quickly as possible. This is
particularly crucial outside of a closely monitored clinical
study, where continuous vigilance and proactive antibiotic
treatment are essential to avoid a potentially fatal infection
(http://soliris.net/sites/default/files/assets/soliris_pi.pdf).
In conclusion, long-term treatment with eculizumab
resulted in sustained improvement in patient outcomes by
rapidly reducing haemolysis and significantly reducing the
frequency of severe and life-threatening morbidities, such
as TEs and CKD, and thus, improving patient survival.
There was evidence that eculizumab improved kidney func-
tion over time and also provided sustained protection
against further renal damage, particularly when adminis-
tered early and prior to advanced renal impairment. Ecu-
lizumab therapy was well tolerated with a favourable safety
profile; very few patients discontinued treatment during
long-term therapy. Over the course of this study, survival
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rates were high and consistent with the improvements
observed in another overlapping cohort of patients in
whom survival was seen to be similar to age- and sex-
matched normal control subjects (Kelly et al, 2011). The
International PNH Registry (www.pnhregistry.com) is
providing further opportunities to continue studying and
understanding the long-term benefits of eculizumab in
patients with PNH outside the clinical trial setting.
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